PMID- 26136131
OWN - NLM
STAT- MEDLINE
DCOM- 20170223
LR  - 20181203
IS  - 2299-8306 (Electronic)
IS  - 0423-104X (Linking)
VI  - 66
IP  - 3
DP  - 2015
TI  - Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory 
      cytokine release in men and women with type 2 diabetes and atherogenic 
      dyslipidemia.
PG  - 224-30
LID - 10.5603/EP.2015.0029 [doi]
AB  - INTRODUCTION: Statins and fibrates reduce monocyte release of proinflammatory 
      cytokines, but it remains unknown whether this effect is sex dependent. MATERIAL 
      AND METHODS: We retrospectively analysed age-, weight-, and lipid-matched 
      populations of type 2 diabetic patients of both sexes, who, because of 
      atherogenic dyslipidaemia, were treated with simvastatin (40 mg daily), 
      fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Monocyte release of 
      tumour necrosis factor alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte 
      chemoattractant protein-1 (MCP-1), as well as circulating levels of 
      high-sensitivity C-reactive protein (hsCRP) and free fatty acids (FFA) were 
      assessed separately for men and women before and after 12 weeks of treatment. 
      RESULTS: Baseline monocyte release of TNF-alpha, interleukin-1beta, interleukin-6, and 
      MCP-1, as well as plasma hsCRP and FFA levels were comparable in both sexes. 
      Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced 
      monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no 
      difference between the treatment groups. The impact of simvastatin and 
      fenofibrate administered alone on monocyte cytokine release and systemic 
      inflammation did not differ between the men and women. The effect of 
      simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 
      and MCP-1 was more pronounced in the male population. The impact of simvastatin 
      administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was 
      also stronger in the men than in the women, but the difference did not reach the 
      level of significance. CONCLUSIONS: The obtained results suggest that sex 
      differences determine the strength of the monocyte-suppressing effect of 
      simvastatin/ /fenofibrate combination therapy in type 2 diabetic patients with 
      atherogenic dyslipidaemia.
FAU - Krysiak, Robert
AU  - Krysiak R
AD  - Department of Internal Medicine and Clinical Pharmacology, Medical University of 
      Silesia, Katowice, Poland. r.krysiak@interia.pl.
FAU - Gdula-Dymek, Anna
AU  - Gdula-Dymek A
FAU - Marek, Bogdan
AU  - Marek B
FAU - Okopien, Boguslaw
AU  - Okopien B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Poland
TA  - Endokrynol Pol
JT  - Endokrynologia Polska
JID - 0370674
RN  - 0 (Cytokines)
RN  - 0 (Hypolipidemic Agents)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - AGG2FN16EV (Simvastatin)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - *Atherosclerosis
MH  - C-Reactive Protein/analysis
MH  - Cytokines/*blood/metabolism
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Dyslipidemias/*complications/drug therapy
MH  - Female
MH  - Fenofibrate/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypolipidemic Agents/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*drug effects/metabolism
MH  - Sex Factors
MH  - Simvastatin/pharmacology/*therapeutic use
EDAT- 2015/07/03 06:00
MHDA- 2017/02/24 06:00
CRDT- 2015/07/03 06:00
PHST- 2014/07/01 00:00 [received]
PHST- 2014/08/12 00:00 [accepted]
PHST- 2015/07/03 06:00 [entrez]
PHST- 2015/07/03 06:00 [pubmed]
PHST- 2017/02/24 06:00 [medline]
AID - VM/OJS/J/38755 [pii]
AID - 10.5603/EP.2015.0029 [doi]
PST - ppublish
SO  - Endokrynol Pol. 2015;66(3):224-30. doi: 10.5603/EP.2015.0029.